Recorded Presentation from the NCCN Pharmacy Updates: Chemoimmunotherapy Updates in Advanced/Metastatic Non-Small Cell Lung Cancer
Advanced non-small cell lung cancer (aNSCLC) is a complex disease state with many variables to consider for systemic therapy selection. Frequently emerging new data can make it challenging for busy health care professionals to stay up to date with the latest options and the data behind them. This webinar will provide a summary of the newest chemoimmunotherapy options in aNSCLC. It is also important for clinicians to be able to recognize the toxicities associated with these combination regimens and counsel their patients on monitoring for and managing them.
Target Audience
This program is designed to meet the educational needs of pharmacists, physicians, nurses, nurse practitioners, physician associates/assistants, and other health care professionals who manage patients with cancer.
Learning Objectives
Following this activity, participants should be able to:
- Describe the place in therapy of the newest chemoimmunotherapy options in advanced non-small cell lung cancer and discuss disease-specific factors to consider such as PD-L1 status and genomic aberrations.
- Summarize clinical evidence for the approvals of cemiplimab-rwlc in combination with platinum-based chemotherapy, and tremelimumab-actl plus durvalumab and platinum-based chemotherapy in aNSCLC.
- Discuss key patient counseling points for cemiplimab-rwlc in combination with platinum-based chemotherapy, and tremelimumab-actl plus durvalumab and platinum-based chemotherapy.
Melvin J. Rivera, PharmD, BCOP
The University of Texas MD Anderson Cancer Center
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below has no relevant financial relationships with ineligible companies to disclose.
Melvin J. Rivera, PharmD, BCOP
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour. This activity offers 1.0 pharmacotherapeutic contact hour for nurses.
Pharmacists
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-24-118-H01-P
Physician Associates/Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until November 12, 2025. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 ANCC Pharmacology Contact Hours
- 1.00 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing